ArticleHuman vaccines & immunotherapeutics2014
Cost-effectiveness of hepatitis A vaccination in Indonesia.
Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Economic evaluation of hepatitis A vaccines by income level of the country: A systematic review.The Indian journal of medical research · 2022Pooled it
- Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine.Human vaccines & immunotherapeutics · 2017Trial
- Hepatitis A virus endemicity and vaccine policy, India.Bulletin of the World Health Organization · 2026Article
- Article
- Article
- Seroprevalence and Shifting Endemicities of Hepatitis A Virus Infection in Two Different Geographical Areas in the Philippines.Infectious diseases and therapy · 2024Article
- Article
- Article
- Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.PLoS neglected tropical diseases · 2021Article
- Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.Human vaccines & immunotherapeutics · 2021Review
- The Effect of E-Learning on the Attitude Toward Dengue Prevention and the Acceptance of Dengue Vaccination.Patient preference and adherence · 2021Article
- Cost-Effectiveness of Ferrous Fumarate-Folic Acid and Ferrous Gluconate-Multivitamins in a High Prevalence Area of Iron Deficiency Anemia in Indonesia.Therapeutics and clinical risk management · 2021Article
- Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs withInternational journal of environmental research and public health · 2020Article
- Globalization and the Changing Epidemiology of Hepatitis A Virus.Cold Spring Harbor perspectives in medicine · 2018Review
- Vaccination of Hepatitis A; To Do or Not to Do?Middle East journal of digestive diseases · 2017Article
- Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.Human vaccines & immunotherapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to assess the cost-effectiveness of hepatitis A immunization in Indonesia, including an explicit comparison between one-dose and two-dose vaccines.
methodsAn age-structured cohort model based on a decision tree was developed for the 2012 Indonesia birth cohort. Using the model, we made a comparison on the use of two-dose and one-dose vaccines. The model involved a 70-year time horizon with 1-month cycles for children less than 2 years old and annually thereafter. Monte Carlo simulations were used to examine the economic acceptability and affordability of the hepatitis A vaccination.
resultsVaccination would save US$ 3,795,148 and US$ 2,892,920 from the societal perspective, for the two-dose and one-dose vaccine schedules, respectively, in the context of hepatitis A treatment. It also would save 8917 and 6614 discounted quality-adjusted-life-years (QALYs), respectively. With the vaccine price of US$ 3.21 per dose, the implementation of single dose vaccine would yield an incremental cost-effectiveness ratio (ICER) of US$ 4933 per QALY gained versus no vaccination, whereas the two-dose versus one-dose schedule would cost US$ 14 568 per QALY gained. Considering the 2012 gross-domestic-product (GDP) per capita in Indonesia of US$ 3557, the results indicate that hepatitis A vaccination would be a cost-effective intervention, both for the two-dose and one-dose vaccine schedules in isolation, but two-dose vaccination would no longer be cost-effective if one-dose vaccination is a feasible option. Vaccination would be 100% affordable at budgets of US$ 71,408 000 and US$ 37,690,000 for the implementation of the two-dose and one-dose vaccine schedules, respectively.
conclusionsThe implementation of hepatitis A vaccination in Indonesia would be a cost-effective health intervention under the market vaccine price. Given the budget limitations, the use of a one-dose-vaccine schedule would be more realistic to be applied than a two-dose schedule. The vaccine price, mortality rate and discount rate were the most influential parameters impacting the ICERs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.